ArticleCancer cell international2025
Novel cyclic C
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUmin was discovered in Curcuma longa L. and/or Curcuma domestica L. C5-curcumin and its derivatives, like synthetic cyclic C5-curcuminoids, are promising anticancer compounds with exceptional pharmacokinetic profiles compared to curcumin.
methodsTo demonstrate their anticancer activities, we tested six novel synthetic cyclic C5-curcuminoids on HeLa, HEC-1A, and T24 tumor cell lines. This investigation focused on ferroptosis and apoptosis, two types of programmed cell death. Ferroptosis-related genes were investigated using real-time polymerase chain reaction (PCR) and Western blotting. The total iron content, reactive oxygen species (ROS) levels, glutathione peroxidase activity, and thiol concentrations were measured to determine ferroptosis. Cytochrome c levels and caspase-3 activity were measured to monitor the apoptosis.
resultsThe study of six synthetic cyclic C5-curcuminoids revealed that their effects on HeLa cells differed from those on HEC-1A and T24 cells, indicating distinct mechanisms of action. Compound 4 notably increased iron accumulation and reactive oxygen species (ROS) production, while decreasing antioxidant defenses in all three carcinoma cell lines, suggesting a ferroptotic response. In contrast, compound 9 was successful in activating caspase-3 in carcinoma cells and inducing apoptosis in the COS-1 control cell line. Notably, compound 4 did not enhance caspase-3 activity in the control cell line. These results highlight compound 4 as a possible synthetic cyclic C5-curcuminoid for the three cancerous cell lines tested.
conclusionRegarding the distinct effects of the examined synthetic cyclic C5-curcuminoids on the three cancer cell types, we hypothesize that their mechanisms of action are different and that divergent target molecules and/or signaling pathways may be involved. However, compounds 4 and 9 were efficient against the three carcinoma cell lines. Further examination of the possible targets could help elucidate which compounds are more suitable for consideration as potential antitumor drug candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.